Study subjects
SECONDARY
374 community-dwelling ambulant post-menopausal women aged (mean [SD]) 68.7[12.3] years with PMO on treatment with oral bisphosphonates were recruited to the first stage of the study (pre-screen study). They were recruited from the metabolic bone clinics in secondary care (CONSORT flowchart, WD: withdrew from study, ITT: intention to treatTable of baseline demographics, biochemical parameters by arm (before any withdrawals) Values are mean (SD)Total HipBMD (g/cmTotal HipT scoreFemoral neckT scoreLumbar spineT scoreParathyroid Hormone (PTH) ng/LRef. range: 10–65 ng/LSerum Vitamin K (µg/L)CTX (µg/L)Ref. range: 0.1–0.5 μg/LP1NP (µg/L)Ref range:Pre- Menopausal women: 30—78 µg/LPost Menopausal women: 26 -110 µg/LThere were no significant differences between the 3 groups